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Objectives (all parts max 100 words) 
Osteogenesis imperfecta (OI) is a heterogeneous condition with no effective cure or 
treatment. Severe, but viable, forms can present in-utero. Early experience indicates that 
transplantation of fetal mesenchymal stem cells (MSC) before and after birth may 
ameliorate symptoms and reduce fracturing. In the Boost Brittle Bones Before Birth 
(BOOSTB4) study we aim to evaluate the safety and efficacy of pre- and/or postnatal MSC 
transplantation in severe viable forms of OI (types III and IV), develop rapid prenatal 
diagnosis based on exome sequencing of fetal cells and cell free DNA in maternal blood. 
 
Methods  
Rapid exome sequencing using a panel targeted for skeletal disorders will allow definitive in-
utero molecular diagnosis of OI. In-utero transplantation in 15 cases will be compared with 
transplantation at 4 months in postnatal cases to determine safety for the fetus, child and 
mother. Outcomes include fracture frequency, growth, bone mineral density to the age of 
20 months. Non-invasive prenatal diagnosis (NIPD) of OI based on analysis of cell free DNA 
will be developed. 
 
Results 
We have established a European network centred around hubs in Stockholm, London, 
Leiden/Utrecht and Berlin. Early studies have shown that rapid diagnosis of skeletal 
dysplasias using exome sequencing is possible. To inform further development of rapid in-
utero diagnosis and NIPD we seek referrals for rapid exome sequencing and development of 
the NIPD panel.  
 
Conclusions 
Demonstration that prenatal transplantation improves early outcome would represent a 
major step forward in the management of patients with severe OI, and beyond to a range of 
other inherited birth defects. The BOOSTB4 consortium welcomes clinical cases for diagnosis 
of OI using rapid exome sequencing or NIPD (contact l.chitty@ucl.ac.uk). The clinical trial on 
treatment of OI with fetal MSC pre- or post-natally will commence early in 2017 (contact 
Cecilia.Gotherstrom@ki.se).  
 
 
 
Learning Objective 
 The participant shall be able to understand the prognosis for severe OI, the potential 
for in-utero therapy and how to participate in this first in man study. 
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